SGRY RSI Chart
Last 7 days
-2.9%
Last 30 days
5.6%
Last 90 days
-24.5%
Trailing 12 Months
-30.1%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 2.8B | 0 | 0 | 0 |
2023 | 2.6B | 2.7B | 2.7B | 2.7B |
2022 | 2.3B | 2.4B | 2.4B | 2.5B |
2021 | 1.9B | 2.1B | 2.2B | 2.2B |
2020 | 1.9B | 1.8B | 1.8B | 1.9B |
2019 | 1.8B | 1.8B | 1.8B | 1.8B |
2018 | 1.5B | 1.7B | 1.9B | 1.8B |
2017 | 1.2B | 1.2B | 1.1B | 1.4B |
2016 | 1.0B | 1.1B | 1.1B | 1.1B |
2015 | 557.0M | 713.0M | 876.3M | 959.9M |
2014 | 314.3M | 343.9M | 373.6M | 403.3M |
2013 | 0 | 0 | 0 | 284.6M |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 14, 2024 | doherty david t | sold | -20,613 | 28.59 | -721 | chief financial officer |
Mar 13, 2024 | evans jason eric | sold | -143,796 | 29.71 | -4,840 | chief executive officer |
Mar 12, 2024 | taparo anthony | sold | -23,507 | 29.87 | -787 | chief growth officer |
Mar 12, 2024 | burkhalter danielle | sold | -3,301 | 29.74 | -111 | chief human resources officer |
Mar 12, 2024 | baldock jennifer | sold | -27,420 | 29.74 | -922 | chief admin & dev officer |
Mar 12, 2024 | owens bradley r. | sold | -82,989 | 29.82 | -2,783 | national group president |
Mar 11, 2024 | taparo anthony | sold | -19,230 | 29.54 | -651 | chief growth officer |
Mar 11, 2024 | burkhalter danielle | sold | -3,757 | 29.59 | -127 | chief human resources officer |
Mar 11, 2024 | evans jason eric | sold | -58,409 | 29.44 | -1,984 | chief executive officer |
Mar 11, 2024 | owens bradley r. | sold | -18,637 | 29.49 | -632 | national group president |
Which funds bought or sold SGRY recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -5.6 | -285,108 | 2,095,140 | -% |
May 16, 2024 | COMERICA BANK | added | 1.24 | -1,727 | 29,271 | -% |
May 16, 2024 | JANE STREET GROUP, LLC | reduced | -41.78 | -2,423,630 | 2,878,300 | -% |
May 15, 2024 | Magnetar Financial LLC | added | 511 | 4,070,490 | 4,935,850 | 0.11% |
May 15, 2024 | Penn Capital Management Company, LLC | new | - | 9,450,210 | 9,450,210 | 0.84% |
May 15, 2024 | SEGALL BRYANT & HAMILL, LLC | added | 19.81 | 961,297 | 9,165,800 | 0.17% |
May 15, 2024 | Man Group plc | new | - | 690,027 | 690,027 | -% |
May 15, 2024 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | added | 51.36 | 27,707,100 | 95,062,300 | 1.65% |
May 15, 2024 | D. E. Shaw & Co., Inc. | new | - | 2,073,960 | 2,073,960 | -% |
May 15, 2024 | Royal Bank of Canada | reduced | -22.02 | -801,000 | 2,135,000 | -% |
Unveiling Surgery Partners Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Surgery Partners Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
UNH | 482.9B | 379.5B | 31.44 | 1.27 | ||||
CI | 96.2B | 206.0B | 24.97 | 0.47 | ||||
HCA | 84.6B | 66.7B | 15.46 | 1.27 | ||||
CVS | 72.4B | 360.9B | 9.89 | 0.2 | ||||
CNC | 41.7B | 155.5B | 15.24 | 0.27 | ||||
DVA | 12.3B | 12.3B | 15.03 | 0.99 | ||||
UHS | 11.9B | 14.7B | 14.63 | 0.81 | ||||
MID-CAP | ||||||||
CHE | 8.5B | 2.3B | 30.15 | 3.73 | ||||
ACHC | 6.2B | 3.0B | -545.12 | 2.06 | ||||
AMEH | 2.3B | 1.5B | 36.62 | 1.57 | ||||
AMN | 2.2B | 3.5B | 15.49 | 0.64 | ||||
SMALL-CAP | ||||||||
ADUS | 1.8B | 1.1B | 27.59 | 1.67 | ||||
BKD | 1.3B | 3.0B | -7.66 | 0.44 | ||||
BEAT | 54.5M | - | -3.61 | - | ||||
AMS | 22.0M | 21.6M | 39.79 | 1.02 |
Surgery Partners Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -2.4% | 717 | 735 | 674 | 668 | 666 | 707 | 621 | 615 | 596 | 610 | 559 | 543 | 512 | 548 | 496 | 375 | 441 | 517 | 452 | 445 | 417 |
Cost Of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 388 | 353 | 340 | 326 |
Operating Expenses | 1.2% | 641 | 634 | 592 | 570 | 620 | 613 | 547 | 539 | 496 | 495 | 496 | 484 | 448 | 452 | 478 | 330 | 418 | 445 | 393 | 390 | 367 |
S&GA Expenses | -100.0% | - | 21.00 | 37.00 | 31.00 | 32.00 | 29.00 | 18.00 | 26.00 | 30.00 | 27.00 | 26.00 | 25.00 | 27.00 | 24.00 | 25.00 | 25.00 | 23.00 | 24.00 | 20.00 | 23.00 | 22.00 |
Income Taxes | -26.7% | 4.00 | 6.00 | 3.00 | -7.80 | -1.60 | 10.00 | 8.00 | 4.00 | 1.00 | 12.00 | 1.00 | -2.70 | 0.00 | -5.60 | 1.00 | -0.60 | -15.20 | 4.00 | 2.00 | 1.00 | 2.00 |
Net Income | -1140.0% | -12.40 | -1.00 | -4.90 | 19.00 | -24.90 | -23.40 | -25.00 | -18.40 | 12.00 | -0.10 | -22.90 | -26.90 | -21.00 | 6.00 | -61.60 | -32.50 | -27.50 | -19.20 | -15.70 | -19.80 | -20.10 |
Net Income Margin | 105.0% | 0.00* | 0.00* | -0.01* | -0.02* | -0.04* | -0.02* | -0.01* | -0.01* | -0.02* | -0.03* | -0.03* | -0.05* | - | - | - | - | - | - | - | - | - |
Free Cashflow | -54.0% | 20.00 | 43.00 | 86.00 | 26.00 | 50.00 | -15.50 | 12.00 | 20.00 | 62.00 | 6.00 | -0.60 | -11.20 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 1.4% | 6,976 | 6,877 | 6,780 | 6,621 | 6,643 | 6,682 | 6,537 | 6,292 | 6,290 | 6,118 | 5,632 | 5,621 | 5,639 | 5,413 | 5,313 | 5,245 | 5,091 | 5,019 | 4,918 | 4,891 | 4,881 |
Current Assets | 0.1% | 896 | 895 | 876 | 810 | 869 | 921 | 738 | 788 | 937 | 946 | 842 | 953 | 1,018 | 802 | 893 | 747 | 615 | 526 | 518 | 529 | 535 |
Cash Equivalents | -5.5% | 185 | 196 | 236 | 177 | 246 | 283 | 155 | 227 | 379 | 390 | 330 | 465 | 542 | 318 | 450 | 327 | 195 | 93.00 | 112 | 118 | 143 |
Inventory | 2.4% | 77.00 | 75.00 | 69.00 | 70.00 | 72.00 | 71.00 | 69.00 | 64.00 | 63.00 | 61.00 | 59.00 | 57.00 | 56.00 | 56.00 | 51.00 | 49.00 | 49.00 | 46.00 | 44.00 | 44.00 | 44.00 |
Goodwill | 1.7% | 4,398 | 4,326 | - | - | - | 4,137 | - | - | - | 3,912 | - | - | - | 3,468 | - | - | - | 3,402 | 3,406 | 3,402 | 3,393 |
Current Liabilities | 0.1% | 523 | 523 | 501 | 459 | 475 | 493 | 624 | 522 | 542 | 537 | 541 | 532 | 575 | 557 | 591 | 571 | 412 | 398 | 382 | 369 | 360 |
Long Term Debt | 3.4% | 2,794 | 2,702 | 2,640 | 2,505 | 2,531 | 2,559 | 3,103 | 3,019 | 3,025 | 2,878 | 2,792 | 2,786 | 2,790 | 2,792 | 2,761 | 2,623 | 2,627 | 2,525 | 2,403 | 2,397 | 2,385 |
Shareholder's Equity | 52.9% | 3,038 | 1,987 | 2,005 | 2,983 | 2,943 | 1,998 | 2,105 | 2,041 | 2,013 | 1,970 | 1,552 | 1,527 | 1,105 | 882 | 801 | 896 | 923 | 983 | 1,007 | 1,045 | 1,084 |
Retained Earnings | -2.2% | -581 | -569 | -568 | -563 | -582 | -557 | -533 | -508 | -490 | -502 | -502 | -479 | -452 | -431 | - | - | -343 | -315 | -284 | -268 | -249 |
Additional Paid-In Capital | -0.1% | 2,496 | 2,498 | 2,495 | 2,501 | 2,478 | 2,478 | 1,623 | 1,619 | 1,625 | 1,622 | 1,306 | 1,298 | 843 | 608 | - | - | 655 | 663 | 670 | 678 | 674 |
Accumulated Depreciation | - | - | - | - | - | - | - | - | - | - | - | - | 231 | 216 | 189 | 171 | 152 | 130 | 111 | 98.00 | 75.00 | 60.00 |
Shares Outstanding | 0.4% | 127 | 127 | 126 | 126 | 126 | 126 | 89.00 | 88.00 | 88.00 | 72.00 | 81.00 | 69.00 | - | - | - | - | - | - | - | - | - |
Minority Interest | 2.2% | 1,071 | 1,047 | 982 | 965 | 981 | 943 | 933 | 885 | 852 | 881 | 796 | 762 | 769 | 767 | 700 | 692 | 687 | 687 | 678 | 686 | 693 |
Float | - | - | - | - | 4,700 | - | - | - | 1,100 | - | - | - | 2,100 | - | - | - | 256 | - | - | - | 175 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -35.0% | 41.00 | 63.00 | 105 | 52.00 | 75.00 | 7.00 | 30.00 | 42.00 | 80.00 | 20.00 | 15.00 | 2.00 | 50.00 | 9.00 | 27.00 | 182 | 29.00 | 25.00 | 57.00 | 27.00 | 21.00 |
Share Based Compensation | 8.9% | 5.00 | 5.00 | 4.00 | 5.00 | 4.00 | 5.00 | 5.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 5.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 3.00 | 3.00 | 2.00 |
Cashflow From Investing | -43.0% | -83.10 | -58.10 | -25.60 | -71.20 | -70.70 | -72.20 | -54.30 | -134 | -47.10 | -190 | -101 | -26.40 | -14.30 | -95.20 | 29.00 | -14.80 | -7.70 | -23.40 | -18.90 | -24.50 | -18.40 |
Cashflow From Financing | 171.1% | 32.00 | -44.60 | -20.40 | -49.00 | -41.20 | 193 | -48.00 | -59.30 | -43.70 | 230 | -48.30 | -53.00 | 188 | -45.80 | 68.00 | -35.40 | 80.00 | -20.60 | -44.10 | -27.30 | -43.90 |
Buy Backs | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Millions | 3 Months Ended | |||
---|---|---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |||
Income Statement [Abstract] | ||||
Revenues | $ 717.4 | $ 666.2 | ||
Operating expenses: | ||||
Salaries and benefits | 215.2 | 202.2 | ||
Supplies | 188.8 | 188.4 | ||
Professional and medical fees | 82.6 | 74.6 | ||
Lease expense | 21.4 | 21.4 | ||
Other operating expenses | 54.1 | 45.6 | ||
Cost of revenues | 562.1 | 532.2 | ||
General and administrative expenses | 33.2 | 32.0 | ||
Depreciation and amortization | 33.7 | 33.7 | ||
Transaction and integration costs | 17.4 | 12.5 | ||
Net loss on disposals, consolidations and deconsolidations | 1.5 | 10.5 | ||
Equity in earnings of unconsolidated affiliates | (2.7) | (3.3) | ||
Litigation settlements | (1.8) | 3.0 | ||
Other income, net | (2.0) | (0.8) | ||
Total operating expenses | 641.4 | 619.8 | ||
Operating income | 76.0 | 46.4 | ||
Interest expense, net | (47.3) | (46.8) | ||
Income (loss) before income taxes | 28.7 | (0.4) | ||
Income tax (expense) benefit | (4.4) | 1.6 | ||
Net income | 24.3 | 1.2 | ||
Less: Net income attributable to non-controlling interests | (36.7) | (26.1) | ||
Net loss attributable to Surgery Partners, Inc. | $ (12.4) | $ (24.9) | ||
Net loss per share attributable to common stockholders: | ||||
Basic (in USD per share) | $ (0.10) | $ (0.20) | ||
Diluted (in USD per share) | [1] | $ (0.10) | $ (0.20) | |
Weighted average common shares outstanding: | ||||
Basic (shares) | 125,972 | 125,206 | ||
Diluted (shares) | [1] | 125,972 | 125,206 | |
|
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 185.2 | $ 195.9 |
Accounts receivable | 494.3 | 496.4 |
Inventories | 77.0 | 75.2 |
Prepaid expenses | 31.7 | 31.0 |
Other current assets | 107.7 | 96.5 |
Total current assets | 895.9 | 895.0 |
Property and equipment, net of accumulated depreciation of $485.4 and $454.4, respectively | 982.8 | 968.7 |
Goodwill and other intangible assets, net | 4,451.1 | 4,380.8 |
Investments in and advances to affiliates | 188.7 | 184.1 |
Right-of-use operating lease assets | 257.7 | 255.3 |
Long-term deferred tax assets | 87.0 | 89.5 |
Other long-term assets | 112.4 | 103.3 |
Total assets | 6,975.6 | 6,876.7 |
Current liabilities: | ||
Accounts payable | 174.1 | 171.8 |
Accrued payroll and benefits | 68.6 | 73.8 |
Other current liabilities | 203.5 | 204.1 |
Current maturities of long-term debt | 77.2 | 73.3 |
Total current liabilities | 523.4 | 523.0 |
Long-term debt, less current maturities | 2,793.8 | 2,701.8 |
Right-of-use operating lease liabilities | 250.5 | 248.9 |
Other long-term liabilities | 46.3 | 41.1 |
Non-controlling interests—redeemable | 323.7 | 327.4 |
Stockholders' equity: | ||
Preferred stock, $0.01 par value; shares authorized - 20,310,000; shares issued or outstanding - none | 0.0 | 0.0 |
Common stock, $0.01 par value; shares authorized - 300,000,000; shares issued and outstanding - 127,101,670 and 126,593,727, respectively | 1.3 | 1.3 |
Additional paid-in capital | 2,495.6 | 2,497.6 |
Accumulated other comprehensive income | 52.0 | 57.5 |
Retained deficit | (581.6) | (569.2) |
Total Surgery Partners, Inc. stockholders' equity | 1,967.3 | 1,987.2 |
Non-controlling interests—non-redeemable | 1,070.6 | 1,047.3 |
Total stockholders' equity | 3,037.9 | 3,034.5 |
Total liabilities and stockholders' equity | $ 6,975.6 | $ 6,876.7 |